Home - ECOG-ACRIN Cancer Research Group
ECOG-ACRIN Cancer Research Group is a worldwide network of 1300 academic and community-based cancer centers and hospitals.| ECOG-ACRIN Cancer Research Group
The post The October 2025 <em>News from ECOG-ACRIN</em> blog is now available appeared first on ECOG-ACRIN Cancer Research Group.| ECOG-ACRIN Cancer Research Group
The post Now Enrolling: STOPGAP II trial opens for patients with stomach cancer appeared first on ECOG-ACRIN Cancer Research Group.| ECOG-ACRIN Cancer Research Group
The post Institution Spotlight: Delaware/ChristianaCare NCORP appeared first on ECOG-ACRIN Cancer Research Group.| ECOG-ACRIN Cancer Research Group
The post Biomarker breakthroughs at ASTRO 2025 (features a discovery from the E3805 CHAARTED prostate cancer trial) appeared first on ECOG-ACRIN Cancer Research Group.| ECOG-ACRIN Cancer Research Group
The post Dr. Xiaolei Shi on validating the APUC-6 signature in metastatic prostate cancer from the E3805 CHAARTED trial appeared first on ECOG-ACRIN Cancer Research Group.| ECOG-ACRIN Cancer Research Group
The post WATCH: Dr. John Varlotto discusses results from study EA5181 at <em>World Conference on Lung Cancer</em> appeared first on ECOG-ACRIN Cancer Research Group.| ECOG-ACRIN Cancer Research Group
Now Enrolling: EAA241 trial opens for patients with newly diagnosed multiple myeloma and kidney failure| ECOG-ACRIN Cancer Research Group
The post The September 2025 <em>News from ECOG-ACRIN</em> blog is now available appeared first on ECOG-ACRIN Cancer Research Group.| ECOG-ACRIN Cancer Research Group
The post Take Action Today: Rally for Medical Research appeared first on ECOG-ACRIN Cancer Research Group.| ECOG-ACRIN Cancer Research Group
The post WATCH: Dr. David Gerber discusses E4512 ALCHEMIST trial data at <em>World Conference on Lung Cancer</em> appeared first on ECOG-ACRIN Cancer Research Group.| ECOG-ACRIN Cancer Research Group
ECOG-ACRIN Cancer Research Group is a worldwide network of 1300 academic and community-based cancer centers and hospitals.| ECOG-ACRIN Cancer Research Group
At #ASCO2025: 64% of early-stage HER2+, ER- breast cancer patients had a pCR with 12 weeks of THP. The CompassHER2 trial could change the chemo standard.#BreastCancer #OncoTwitter #ECOGACRIN #ClinicalResearch| ECOG-ACRIN Cancer Research Group
Group-wide meetings of the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) occur twice a year and are open to researchers and staff affiliated with member institutions, patient advocates who are members of ECOG-ACRIN's various scientific committees, industry representatives, and invited individuals from external (non-member) organizations. Group meetings are closed to the public.| ECOG-ACRIN Cancer Research Group
Description| ECOG-ACRIN Cancer Research Group
